Workflow
pharmaceuticals
icon
Search documents
Stock Market Today: Dow Futures Rise After Trump Unveils New Tariffs
WSJ· 2025-09-26 08:08
President Trump says he will slap new levies on pharmaceuticals and big trucks ...
Neogen Corporation (NEOG) Slid Due to Below-Expected Revenue and Profitability
Yahoo Finance· 2025-09-24 13:06
Group 1 - Fred Alger Management's "Alger Weatherbie Specialized Growth Fund" reported a 10.94% gain for Q2 2025, with Class A shares outperforming the Russell 2500 Growth Index [1] - Initial market volatility in April was due to trade policy uncertainty following President Trump's tariffs, but stability returned with a 90-day pause on new duties [1] - Market sentiment improved in May after the White House suspended reciprocal tariff hikes on China, contributing to the S&P 500 reaching a record high in June [1] Group 2 - Neogen Corporation (NASDAQ:NEOG) focuses on food and animal safety, but its stock experienced a -2.44% return over the last month and a 65.98% decline over the past 52 weeks [2] - As of September 23, 2025, Neogen's stock closed at $5.60 per share, with a market capitalization of $1.217 billion [2] - Neogen's performance was negatively impacted by fiscal third-quarter revenue and profitability falling below expectations, leading to a modest reduction in full-year 2025 guidance due to a weaker macroeconomic environment [3] Group 3 - Neogen Corporation was held by 28 hedge fund portfolios at the end of Q2 2025, an increase from 15 in the previous quarter, indicating growing interest [4] - Despite the potential of Neogen as an investment, certain AI stocks are viewed as having greater upside potential and lower downside risk [4]
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2026 on October 30
Prnewswire· 2025-09-23 10:45
Financial Results Announcement - Cardinal Health plans to release first-quarter financial results for fiscal year 2026 on October 30, prior to the opening of trading on the New York Stock Exchange [1] - A webcast discussion of these results will begin at 8:30 a.m. Eastern [1] Webcast Access - The webcast and corresponding slide presentation can be accessed via Cardinal Health's Investor Relations page without an access code [2] - Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months [2] Company Overview - Cardinal Health is a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient products and services, and an operator of nuclear pharmacies and manufacturing facilities [3] - The company provides performance and data solutions and is a global manufacturer and distributor of medical and laboratory products [3] - Cardinal Health's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives [3]
FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian
Yahoo Finance· 2025-09-22 21:32
Group 1 - Merck & Co., Inc. has received Breakthrough Therapy Designation from the FDA for raludotatug deruxtecan, targeting platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment [2][3] - The designation is based on data from a phase 1 trial and the ongoing REJOICE-Ovarian01 phase 2/3 study, aimed at accelerating development for patients with significant unmet needs [3] - Approximately 65% of ovarian cancer patients express CDH6, and up to 80% experience relapse after standard therapies, highlighting the drug's potential impact [3] Group 2 - Merck & Co., Inc. is recognized as one of the best stocks to invest in for financial stability and is involved in developing pharmaceuticals, vaccines, biologics, and animal health products [1][4] - The collaboration between Merck and Daiichi Sankyo marks the second breakthrough designation for their oncology partnership, which began in October 2023 [3]
Novartis ramps up US stockpiles to shield against potential tariffs
Invezz· 2025-09-20 14:41
Core Viewpoint - Novartis AG has significantly increased its stockpiles of pharmaceuticals in the United States to prepare for potential tariffs [1] Company Summary - The Chief Executive Officer Vas Narasimhan indicated that the company is positioning itself strategically to withstand potential tariffs [1]
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
Reuters· 2025-09-20 10:00
Core Viewpoint - Novartis has proactively increased its stockpiles of pharmaceuticals in the United States to mitigate potential impacts from President Donald Trump's tariffs on its products [1] Company Summary - The chief executive of Novartis indicated that the company is well prepared for any adverse effects that may arise from the tariffs imposed by the U.S. government [1]
President Donald Trump says new semiconductor tariff plan coming as soon as next week
CNBC Television· 2025-08-05 13:16
Trade & Tariffs - A deal exists involving \$600 billion for unspecified investments, aimed at recouping past losses [1] - The speaker expressed frustration over a \$41 billion deficit with Switzerland, despite minimal tariffs [2] - Tariffs on specific excluded classes like steel and aluminum will be announced soon [4] Semiconductor & Pharmaceutical Industries - Tariffs will be imposed on semiconductors and chips to encourage domestic production in the United States [5] - A major Taiwanese company is investing \$300 billion in Arizona to build a large chip and semiconductor plant [5] - Initially small tariffs on pharmaceuticals will increase to 150% within one year and up to 250% within one and a half years to promote domestic production [6]
X @Investopedia
Investopedia· 2025-07-18 14:00
Potential Impacts of Tariffs - Proposed tariffs on pharmaceuticals could lead to higher prices [1] - Higher insurance premiums are a potential consequence of the tariffs [1] - Drug shortages are a possible risk associated with the tariffs [1]
Trump to Impose Drug, Chip Tariffs, Announces Indonesia Trade Deal
Bloomberg Television· 2025-07-16 05:43
Pharmaceuticals will be tariff probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build. And then we're going to make it a very high tariff. For more, let's bring in senior editor Bill Faries.Let's just start with those comments out of President Trump suggesting that tariffs could be coming for both pharmaceuticals and potentially for chip makers as well. Bill, what more do we know. Yeah.So the timeline is is really new here ...
X @Bloomberg
Bloomberg· 2025-07-16 01:19
Trade Policy - Potential tariffs on pharmaceuticals may be imposed by the end of the month [1] - Tariffs on semiconductors could be implemented soon [1]